Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Johnson and Johnson
Medtronic
McKesson
Moodys

Last Updated: July 3, 2022

CLINICAL TRIALS PROFILE FOR ZUBSOLV


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Zubsolv

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01848054 ↗ Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence Completed Worldwide Clinical Trials Phase 3 2013-06-01 The purpose of the study was to assess the efficacy of induction treatment with buprenorphine/naloxone (BNX) sublingual tablet s compared with induction treatment with buprenorphine only. The hypothesis is that starting directly on OX219 works equally well (e.g. not significantly worse) as starting on buprenorphine only and switching to OX219 on Day 3.
NCT01848054 ↗ Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence Completed Orexo AB Phase 3 2013-06-01 The purpose of the study was to assess the efficacy of induction treatment with buprenorphine/naloxone (BNX) sublingual tablet s compared with induction treatment with buprenorphine only. The hypothesis is that starting directly on OX219 works equally well (e.g. not significantly worse) as starting on buprenorphine only and switching to OX219 on Day 3.
NCT01903005 ↗ Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence Completed Worldwide Clinical Trials Phase 4 2013-07-01 The purpose of this study was to assess safety, efficacy, and treatment retention following extended treatment with OX219, a higher-bioavailability buprenorphine/naloxone (BNX) sublingual tablet formulation in opioid-dependent patients who completed 1 of 2 primary efficacy and safety studies of OX219.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zubsolv

Condition Name

Condition Name for Zubsolv
Intervention Trials
Opioid Dependence, on Agonist Therapy 2
Opiate Dependence 1
Opioid Dependence 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zubsolv
Intervention Trials
Opioid-Related Disorders 5
Anemia, Sickle Cell 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zubsolv

Trials by Country

Trials by Country for Zubsolv
Location Trials
United States 52
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zubsolv
Location Trials
Maryland 4
Florida 4
Massachusetts 3
California 3
Alabama 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zubsolv

Clinical Trial Phase

Clinical Trial Phase for Zubsolv
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zubsolv
Clinical Trial Phase Trials
Completed 5
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zubsolv

Sponsor Name

Sponsor Name for Zubsolv
Sponsor Trials
Worldwide Clinical Trials 3
Orexo AB 3
Indivior Inc. 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zubsolv
Sponsor Trials
Industry 5
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Boehringer Ingelheim
Harvard Business School
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.